Table 1.
Demographic and clinicotherapeutic characteristics of 157 patients
| Characteristic | Interval ≤ 7 wks (n = 60) | Interval > 7 wks (n = 97) | P value |
|---|---|---|---|
| Interval, days | 44 (26‐49) | 55 (50‐78) | <.001a, b , a, b |
| Radiation proctitis | 9 (15.0) | 31 (32.0) | 0.018a, b , c |
| Gender | 0.183c | ||
| Women | 17 (28.3) | 31 (32.0) | |
| Men | 43 (71.7) | 66 (68.0) | |
| Age, y | 55 ± 10 | 52 ± 12 | 0.068d |
| BMI, kg/m2 | 22.7 ± 3.1 | 22.1 ± 2.6 | 0.201d |
| ASA score | 0.910b | ||
| 1 | 7 (11.7) | 13 (13.4) | |
| 2 | 52 (86.7) | 83 (85.6) | |
| 3 | 1 (1.6) | 1 (1.0) | |
| Clinical T classification | 0.240b | ||
| cT2 | 2 (3.3) | 4 (4.1) | |
| cT3 | 47 (78.3) | 64 (66.0) | |
| cT4 | 11 (18.4) | 29 (29.9) | |
| Clinical N classification | 0.462c | ||
| cN0 | 15 (25.0) | 21 (21.6) | |
| cN1 | 20 (33.3) | 42 (43.3) | |
| cN2 | 25 (41.7) | 34 (35.1) | |
| Distance of tumor from anal verge, cm | 0.663b | ||
| >10 | 3 (5.0) | 8 (8.2) | |
| 5‐10 | 31 (51.7) | 44 (45.4) | |
| <5 | 26 (43.3) | 45 (46.4) | |
| Chemotherapy regimen | 0.624c | ||
| 5‐FU | 30 (50.0) | 41 (42.3) | |
| FOLFOX | 30 (50.0) | 56 (57.7) |
Data are median (range), n (%) or mean ± SD.
Abbreviations: BMI, body mass index; ASA, American society of Anesthesiologists; 5‐FU, 5‐fluorouracil; FOLFOX, 5‐Fluorouracil + oxaliplatin + leucovorin.
a
Statistically significant.
b
Data were calculated using the Mann‐Whitney U test.
c
Data were calculated using the χ2 test.
d
Data were calculated using the t test.
Data were calculated using the Fisher exact test.